Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?

[1]  J. Bobes,et al.  Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls , 2018, European Psychiatry.

[2]  J. Rybakowski,et al.  Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review , 2017, Schizophrenia Research.

[3]  J. J. Meana,et al.  Biomarcadores en Psiquiatría: entre el mito y la realidad clínica , 2017 .

[4]  J. Meana,et al.  Biomarkers in Psychiatry: Between myth and clinical reality. , 2017, Revista de psiquiatria y salud mental.

[5]  S. Djurovic,et al.  Persistent increase in TNF and IL‐1 markers in severe mental disorders suggests trait‐related inflammation: a one year follow‐up study , 2017, Acta psychiatrica Scandinavica.

[6]  G. Carrà,et al.  Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis , 2017, Neuroscience & Biobehavioral Reviews.

[7]  A. Teixeira,et al.  Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia. , 2017, Comprehensive psychiatry.

[8]  E. Vasar,et al.  Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia , 2017, European Psychiatry.

[9]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[10]  J. Bobes,et al.  Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. , 2016 .

[11]  S. Djurovic,et al.  Inflammatory evidence for the psychosis continuum model , 2016, Psychoneuroendocrinology.

[12]  M. Koola.  Cytokines in Schizophrenia: Hope or Hype? , 2016, Indian journal of psychological medicine.

[13]  G. Zunta-Soares,et al.  Interaction of BDNF with cytokines in chronic schizophrenia , 2016, Brain, Behavior, and Immunity.

[14]  B. Misiak,et al.  Profiling cognitive impairment in treatment-resistant schizophrenia patients , 2016, Psychiatry Research.

[15]  R. Lenroot,et al.  Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume , 2015, Molecular Psychiatry.

[16]  G. Zunta-Soares,et al.  Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia , 2015, Schizophrenia Research.

[17]  P. McKenna,et al.  Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS) , 2015, Schizophrenia Research.

[18]  M. Maes,et al.  High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[19]  S. Djurovic,et al.  Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls , 2015, Schizophrenia Research.

[20]  J. Bobes,et al.  Psychometric evaluation of the negative syndrome of schizophrenia , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[21]  Peter B. Jones,et al.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.

[22]  R. Heaton,et al.  The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China , 2012, Schizophrenia Research.

[23]  P. Rocca,et al.  Negative symptoms and everyday functioning in schizophrenia: A cross-sectional study in a real world-setting , 2014, Psychiatry Research.

[24]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[25]  A. Gadelha,et al.  Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia , 2014, Physiology & Behavior.

[26]  R. Kahn,et al.  Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment , 2014, Schizophrenia Research.

[27]  D. Velligan,et al.  Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: Potential role for IL-17 pathway , 2013, Schizophrenia Research.

[28]  P. Fusar-Poli,et al.  Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis , 2013, Schizophrenia Research.

[29]  O. Andreassen,et al.  Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder , 2013, Schizophrenia Research.

[30]  Fang Wang,et al.  Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia , 2012, Psychiatry Research.

[31]  J. Moreira,et al.  Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. , 2012, Journal of psychiatric research.

[32]  K. Nuechterlein,et al.  The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain , 2012, Schizophrenia Research.

[33]  Raquel E. Gur,et al.  journal homepage: www. elsevier.com/locate/schres Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS) , 2022 .

[34]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[35]  M. Schwarz,et al.  Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. , 2011, Pharmacology & therapeutics.

[36]  R. Gur,et al.  Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. , 2011, Schizophrenia bulletin.

[37]  J. Bobes,et al.  Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. , 2011 .

[38]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[39]  Liang Liu,et al.  Tyrosine hydroxylase, interleukin-1β and tumor necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis , 2010, Psychiatry Research.

[40]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[41]  Emmanuel Stip,et al.  Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review , 2008, Biological Psychiatry.

[42]  L. San,et al.  Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia , 2004, Schizophrenia Research.

[43]  C. Stefanis,et al.  Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients , 2001, Schizophrenia Research.

[44]  Yong-Ku Kim,et al.  Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics , 2000, Schizophrenia Research.

[45]  V. Peralta,et al.  Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia , 1994, Psychiatry Research.